louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01160757: A Study to Determine the Safety and Efficacy of an Ultrasound Device in the Management of Acute Acne Lesions
Official title: A Study to Determine the Safety and Efficacy of an Ultrasound Device in the Management of Acute Acne Lesions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Acne Vulgaris
Lead sponsor: Arizona State University
Sponsor class: OTHER
First posted: 2010-07-12
Enrollment: 35
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to find out how effective and safe an experimental ultrasound device is for treating Acute Acne lesions.

Detailed description: Acne vulgaris is a disease that occurs when oil and dead skin cells clog the pores of the skin. When the skin's pores are clogged, red spots and bumps known as pimples are formed, usually on the face, neck, chest, and back. In adolescents and adults, acne vulgaris is commonly called "acne." Many factors have been associated with acne. One of the factors is the increased production of fatty substances from an enlarged sebaceous gland ("oil gland").

The experimental ultrasonic device uses sound waves (called ultrasonic waves) to heat the acute acne lesion and the surrounding sebaceous ("oil") glands deep in the skin without affecting the surface of the skin. We hope that heating the sebaceous glands will reduce their size and reduce the symptoms of inflamed acne. Using ultrasonic waves to treat acne is investigational.

This is a pilot study. A pilot study is done on a small group of subjects to learn if the device will be effective and safe, before the device is used on a larger group of subjects.

Eligibility criteria: Inclusion Criteria:

* female or male subjects,
* greater than 18 years age,
* with acute acne on the face.

Exclusion Criteria:

* pregnancy,
* concomitant skin diseases,
* severe acne,
* antibiotic therapy.

Primary outcomes:
measure: Time to clear acute acne lesions
timeFrame: 12 days
Secondary outcomes:
Other outcomes:
Locations:
city: Phoenix
country: United States
facility: Arizona State University, College of Nursing and Healthcare Innovation
state: Arizona
Study officials:
affiliation: ASU, College of Nursing and Healthcare Innovation
name: Denise Link, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06173557: Intraoperative Measurement Technique
Official title: Intraoperative Measurement Technique for Improved Accuracy of Femoral Offset and Leg Length in Total Hip Replacement: A Retrospective Cohort Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Total Hip
Limb Length Discrepancy
Keywords: total hip replacement
limb length discrepancy
Lead sponsor: Ziv Medical Center
Sponsor class: OTHER
First posted: 2023-12-15
Enrollment: 50
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 50 consecutive patients who were admitted to the orthopedic department for elective THR

Brief summary: This retrospective cohort study included 50 consecutive patients who underwent THR. All surgeries were performed by the same orthopedic surgeon, using posterior approach. In all patients, the same technique of intraoperative measurement of the femoral offset and limb length was used, entailed calculation of the distances between reference points on the ischium, greater trochanter, and the screwdriver. Measurements were collected from radiographic imaging data and surgical reports.

Detailed description: Introduction: Restoration of limb length equality and femoral offset is critical for the success of THR. The purpose of this study was to investigate the efficacy of a novel intraoperative measurement technique in minimizing errors in leg length and offset in total hip replacement (THR).

Methods: This retrospective cohort study included 50 consecutive patients who underwent THR. All surgeries were performed by the same orthopedic surgeon, using posterior approach. In all patients, the same technique of intraoperative measurement of the femoral offset and limb length was used, entailed calculation of the distances between reference points on the ischium, greater trochanter, and the screwdriver. Measurements were collected from radiographic imaging data and surgical reports.

Eligibility criteria: Inclusion Criteria:

\* patients that underwent THR due to primary osteoarthritis of the hip joint.

Exclusion Criteria:

* Patients who underwent THR for any other reasons
* patients that underwent revision surgery

Primary outcomes:
measure: outcome
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00738257: A Prospective, Multicentre, Open-label Randomised Controlled Study to Investigate the Effectiveness of Pamidronate in the Prevention of Bone Loss in de Novo Renal Transplant Patients.
Official title: A 2 Year Prospective, Multicentre, Open-label, Randomised, Controlled Study to Investigate the Effectiveness of Pamidronate in the Prevention of Bone Loss in de Novo Renal Transplant Patients (With a PTH > 150pg/ml) on a Ciclosporin A and Glucocorticoid Based Immunosuppressive Regimen.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Bone Loss
Keywords: Renal
transplant,
pamidronate,
ciclosporin,
Ciclosporin A,
steroids,
bone mineral density,
fracture rates
immunosuppressive
regimen
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2008-08-20
Enrollment: 126
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study was to evaluate the effect of Pamidronate on bone mineral density loss and fracture rates up to 2 years, in post renal-transplant subjects on a Ciclosporin A and glucocorticoid based immunosuppressive regimen.


Eligibility criteria: Inclusion Criteria:

1. First or second kidney transplant recipients, aged 18-75 years, PTH \> 150 pg/ml
2. De novo patients scheduled to receive ciclosporin A and prednisolone based immunosuppression.

Exclusion Criteria:

1. Previous or current bone disease unrelated to end stage renal failure.
2. Patients with PTH \< 150pg/ml who may be at risk of adynamic bone disease.
3. Treatment at any time with a bisphosphonate.
4. d. Calcitonin treatment during the previous month.
5. Malignancy (current or history within last 5 years)
6. Pregnancy or lactation, or women of childbearing potential unwilling to use an effective form of contraception for the 12 month duration of the study.

Protocol-defined inclusion/exclusion criteria may apply.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Frimley
country: United Kingdom
facility: Novartis Investigative Site
Study officials:
affiliation: Royal London Hospital
name: John Cunningham, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Walsh SB, Altmann P, Pattison J, Wilkie M, Yaqoob MM, Dudley C, Cockwell P, Sweny P, Banks LM, Hall-Craggs M, Noonan K, Andrews C, Cunningham J. Effect of pamidronate on bone loss after kidney transplantation: a randomized trial. Am J Kidney Dis. 2009 May;53(5):856-65. doi: 10.1053/j.ajkd.2008.11.036.
Clinical trial NCT00145457: IGF1 Generation Test
Official title: A Multicentre Study on the Capacity of the IGF-1 Stimulation Test to Predict the Growth Promoting Effect of Standard and High Doses of Genotonorm® in Prepubertal Children With Growth Hormone Deficiency.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Growth Hormone Deficiency
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2005-09-05
Enrollment: 82
Sex: ALL
Minimum age (years): 4
Maximum age (years): 11
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To assess the predictive value of the short term IGF-1 stimulation test, based on IGF-1 changes, on the 24 months growth response to 2 different doses of GH in patients with conventional GH deficiency.


Eligibility criteria: Inclusion Criteria:

* Male or female aged of more than 4 years.
* GHD defined as a peak GH level \< 20 mUI/ml at two different pharmacological GH provocative tests including one done with two pharmacological agents and both performed within the year before the inclusion, according to the current recommendations of the French Health Authorities

Exclusion Criteria:

* Previous treatment with GH
* Ongoing pharmacological treatment with steroids except if corresponding to substitutive therapy

Primary outcomes:
measure: Change of height standard deviation score after 24 months of treatment according to the short term response of plasma IGF1 to Genotonorm.
Secondary outcomes:
Other outcomes:
Locations:
city: BesanÃ§on
country: France
facility: Pfizer Investigational Site
city: Bordeaux
country: France
facility: Pfizer Investigational Site
city: Dunkerque
country: France
facility: Pfizer Investigational Site
city: Limoges Cedex
country: France
facility: Pfizer Investigational Site
city: Nice
country: France
facility: Pfizer Investigational Site
city: Paris Cedex 14
country: France
facility: Pfizer Investigational Site
city: Tarbes
country: France
facility: Pfizer Investigational Site
city: Toulouse Cedex 9
country: France
facility: Pfizer Investigational Site
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT06148857: Total Corneal Astigmatism Prevalence in Cataract Patients
Official title: Prevalence Data for Total Corneal Astigmatism in Cataract Surgery Candidates
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Cataract
Keywords: cataract
astigmatism
prevalence
Lead sponsor: Peking University Third Hospital
Sponsor class: OTHER
First posted: 2023-11-28
Enrollment: 11000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All the patients who underwent cataract surgery in the Department of Ophthalmology, Peking University Third Hospital from January 2019 to May 2023.

Brief summary: The purpose of this study is to report the prevalence data for total corneal astigmatism (TCA) in cataract surgery candidates.

Detailed description: The purpose of this retrospective study is to report the prevalence data for total corneal astigmatism (TCA) in cataract surgery candidates. Preoperative biometric data of all the patients who underwent cataract surgery in the Department of Ophthalmology, Peking University Third Hospital, from January 2019 to May 2023, were collected and analyzed. Data sets with incomplete biometric data were excluded.

Eligibility criteria: Inclusion Criteria:

* Patients who underwent cataract surgery in the Department of Ophthalmology, Peking University Third Hospital from January 2019 to May 2023.

Exclusion Criteria:

* Incomplete biometric data .

Primary outcomes:
measure: total keratometric astigmatism
timeFrame: At Enrollment
measure: Abulafia-Koch formula total corneal astigmatism
timeFrame: At Enrollment
measure: Barrett toric calculator total corneal astigmatism
timeFrame: At Enrollment
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking University Third Hospital
state: Beijing
Study officials:
affiliation: Peking University Third Hospital
name: Hong Qi, Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04295057: Register of Therapeutical Patients Over 60 Years
Official title: Register on the Study of Prevalence and Incidence, Risk Factors and Outcomes of Hospitalizations in Older Age Groups in Eurasia.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Men
Age Problem
Therapeutic Alliance
Keywords: register
therapy
Lead sponsor: Eurasian Association of Therapists
Sponsor class: OTHER
First posted: 2020-03-04
Enrollment: 12000
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Anonymous men and women in the age group over 60 see a doctor for any reason.

Brief summary: Register for the study of the prevalence and burden of diseases, risk factors and outcomes of hospitalizations in older age groups in the countries of Eurasia.

Detailed description: An open, multicenter registry to track all major noncommunicable diseases and risk factors in older age groups, prescribed drugs, and disease outcomes.

Eligibility criteria: Inclusion Criteria:

* over 60 years
* Appointment to a doctor of a therapeutic profile

Exclusion Criteria:

* Reluctance of the Patient to participate in the Register;
* Age under 60 at the time of inclusion in the Register.

Primary outcomes:
measure: Incidence
timeFrame: 12 months
measure: Non-infectious diseases
timeFrame: 12 months
measure: Age groups
timeFrame: 12 months
measure: Therapy
timeFrame: 12 months
measure: Drugs
timeFrame: 12 months
measure: Measure criteria
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Moscow
country: Russian Federation
facility: Eurasian Association of Therapists
Study officials:
References:
Clinical trial NCT02322957: A Study Investigating the Pharmacokinetics of FV-100 With and Without Ritonavir in Healthy Volunteers
Official title: A Phase 1 Study Investigating the Pharmacokinetics of FV-100 With and Without Ritonavir in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Acute Herpes Zoster
Lead sponsor: ContraVir
Sponsor class: UNKNOWN
First posted: 2014-12-23
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This study is designed to evaluate the potential for a PK drug-drug interaction between FV-100 and ritonavir. The study is a single-center, open-label, randomized, 2-way crossover design in healthy volunteers.


Eligibility criteria: Inclusion Criteria:

* Capable of giving written informed consent
* Non-tobacco user for at least 3 months prior to selection
* Healthy on the basis of physical examination, medical history, ECG and clinical laboratory testing at screening

Exclusion Criteria:(must NOT meet the following)

* Infected with Hepatitis A, B, C, or HIV
* History of or any current medical condition which could impact safety of the participant
* A positive urine drug test
* Consumption of more than 2 units of alcoholic beverages per day or more than 14 per week
* Received an investigational drug or vaccine or used an investigational medical device within 3 months or 5 half-lives before the planned start of treatment or prior treatment with FV-100
* Subjects who have used any drugs or substances known to inhibit or induce cytochrome(CYP) P450 enzymes and/or P-gp within 28 days prior to the first dose and throughout study
* Subjects who have, within 2 weeks prior to the first dose of study drug, ingested grapefruit or grapefruit juice, apple or orange juice, vegetables from the mustard green family or charbroiled meats

Primary outcomes:
measure: The evaluation of safety of a single oral dose of FV-100 alone and when combined with a single oral dose of ritonavir
timeFrame: Two weeks
measure: The evaluation of the pharmacokinetics of FV-100 and CF-1743 following a single oral dose of FV-100 administered alone and with a single oral dose of ritonavir
timeFrame: Two weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02724657: Buteyko Method for Asthmatic Children With Mouth Breathing
Official title: THE EFFECTS OF THE BUTEYKO METHOD IN MOUTH BREATHING ASTHMATIC CHILDREN: A CONTROLLED RANDOMIZED STUDY
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Asthma
Mouth Breathing
Keywords: Child
Breathing exercises
Lead sponsor: Universidade Federal do Rio Grande do Norte
Sponsor class: OTHER
First posted: 2016-03-31
Enrollment: 35
Sex: ALL
Minimum age (years): 7
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To assess the effectiveness of the Buteyko method as an adjunct therapy in the treatment of asthmatic children with mouth breathing.


Eligibility criteria: Inclusion Criteria:

* Children from 7 up to 12 years old with asthma diagnose
* Regular inhaled corticosteroids with no change in dose in the preceding 4 weeks.
* Children cannot present: other respiratory disease (such as cystic fibrosis, bronchiectasis, and tuberculosis), retinal detachment, hypertensive crisis, congenital heart defect, pulmonary edema, history of lobectomy or lung segmentectomy, respiratory infections 15 days prior to the evaluations.

Exclusion Criteria:

* Children that are not able to perform some of the necessary procedures, give up participating in the research and present acute symptoms of respiratory tract during the assessments.

Primary outcomes:
measure: Change in Sleep disturbance (questionnaire)
timeFrame: Baseline, three weeks later and six months after treatment
Secondary outcomes:
measure: Change in spirometry (FVC, FEV1, FEV1/FVC, FEF25-75%, PEF)
timeFrame: Baseline, three weeks later and six months after treatment
measure: Change in ventilometry (minute volume and vital capacity)
timeFrame: Baseline, three weeks later and six months after treatment
measure: Number of hospitalizations
timeFrame: Through study completion, an average of three weeks and six months after treatment
measure: Number of days off-school
timeFrame: During the three weeks of treatment
Other outcomes:
Locations:
city: Natal
country: Brazil
facility: Universidade Federal do Rio Grande do Norte (UFRN)
state: Rio Grande do Norte
Study officials:
References:
Clinical trial NCT03102957: Cartography of Functional and Epileptic Cerebral Areas by Functional MRI and Electroencephalography in Epileptic Patients Before and After Surgery
Official title: Cartography of Functional and Epileptic Cerebral Areas by Functional MRI and Electroencephalography in Epileptic Patients Before and After Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Epilepsy
Lead sponsor: University Hospital, Grenoble
Sponsor class: OTHER
Collaborators: name: Laboratoire de Psychologie et NeuroCognition
First posted: 2017-04-06
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: 2 arms : epileptic patient and healthy volonteers
Primary purpose: BASIC_SCIENCE

Brief summary: Exploring the reorganization (plasticity) of neuroanatomic networks associated with language and memory in patients with left (or dominant hemisphere) temporal lobe epilepsy using functional MRI (fMRI)

Detailed description: The purpose of this study is to explore the reorganization of neuroanatomic networks associated with language and memory in adult patients with temporal lobe epilepsy (ELT). By using functional MRI, patients will be examined before and after surgery. Cerebral plasticity, defined in terms of intrinsic variables such as the topography of the activated regions, will be explored according to some extrinsic factors such as the age at onset of crises (before or after 5-6 years), whether or not Hippocampal sclerosis, hemispheric predominance of language (left or right).

Eligibility criteria: Inclusion Criteria:

* epileptic patients
* medical exam before inclusion
* social security affiliation
* Pharmaco-resistant epilepsy

Exclusion Criteria:

* MRI contraindication
* pregnant women
* breastfeeding mothers
* person under tutorship

Primary outcomes:
measure: neuronal reorganization exploration in language and memory area thanks to functionnal MRI
timeFrame: one hour for each exam
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University Hospital, Grenoble
name: Alexandre KRAINIK, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05351957: Dry Needling for Treating Spasticity in Multiple Sclerosis
Official title: Dry Needling for Treating Spasticity in Multiple Sclerosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Multiple Sclerosis
Keywords: Dry needling, multiple sclerosis, physiotherapy
Lead sponsor: Hospital Universitario de Canarias
Sponsor class: OTHER
First posted: 2022-04-28
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The aim of the study is to evaluate the efficacy of dry needling (DN) in the treatment of spasticity in patients with multiple sclerosis (MS). \[Participants and Methods\] participants with MS, with no evidence of a relapse in the last four weeks and with an EDSS (Expanded Disability Sta- tus Scale) greater than 2.5 points (related with pyramidal score) were recruited. DN was performed in lower limbs for 12 consecutive sessions and evaluated with: EDSS (Pyramidal item), Time up and go (TUG), 25 foot, 9hold peg test (9HPT) and the improvement or not in the quality of life (MSQol54) was verified before and after treatment. A follow up visit was carried out to assess improvement.


Eligibility criteria: Inclusion Criteria:

* Being a patient diagnosed with multiple sclerosis.
* Being over 18 years of age and less than or equal to 60 years of age.
* Having a score equal to or greater than 2 in the EDSS.
* They need to have a measurement in the following functional systems: P (pyramidal) \>2, CT (brainstem), gait \>2 and sphincter \>2.
* They need to present hypertonia or contractures of the muscles selected for the dry needling, the pain expressed by the patients must be a consequence of spastic processes, have hourly availability to receive therapies and not have needle phobias.

Exclusion Criteria:

* Having a disease associated with multiple sclerosis that is incompatible with dry needling.
* Being in relapse, or having suffered it in the thirty days prior to starting the treatment. program or taking medications that are contraindicated with the technique applied in the study, (oral anticoagulants.)

Primary outcomes:
measure: Change in 9HOLD PEG TEST score
timeFrame: inmediatly before and inmediatly after intervention
measure: Change in 25 foot walk score
timeFrame: inmediatly before and inmediatly after intervention
measure: Change in Time up and go test score
timeFrame: inmediatly before and inmediatly after intervention
measure: Change in Expanded Disability Status Scale (EDSS) score
timeFrame: inmediatly before and inmediatly after intervention
measure: Change in Multiple sclerosis Quality of life-54 (MSQol54) score
timeFrame: inmediatly before and inmediatly after intervention
Secondary outcomes:
Other outcomes:
Locations:
city: La Laguna
country: Spain
facility: Hospital Universitario de Canarias
state: Santa Cruz De Tenerife
Study officials:
affiliation: Hospital Universitario de Canarias
name: MONSERRAT GONZÁLEZ-PLATAS
role: STUDY_DIRECTOR
References: